Published in J Surg Res on October 21, 2013
Viral Therapy in Treating Patient With Liver Cancer | NCT01628640
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther (2014) 0.90
Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. ILAR J (2016) 0.77
Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment. Oncotarget (2016) 0.75
Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy. Oncolytic Virother (2015) 0.75
Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy. Viruses (2016) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. Nature (2005) 5.30
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med (2000) 4.37
Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity (2000) 3.07
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 2.72
Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med (2007) 2.15
Relative sensitivities of viruses to different species of interferon. J Virol (1969) 2.02
Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol (2001) 1.92
The low-density lipoprotein receptor gene family: multiple roles in lipid metabolism. J Mol Med (Berl) (1999) 1.82
Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life (2000) 1.81
Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem (1997) 1.76
LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A (2013) 1.75
Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res (2001) 1.73
Vesicular stomatitis virus as an oncolytic vector. Viral Immunol (2004) 1.70
Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther (2009) 1.54
Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology (2004) 1.53
Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res (2003) 1.50
Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. J Virol (1993) 1.39
Cooperation of B cells and T cells is required for survival of mice infected with vesicular stomatitis virus. Int Immunol (1997) 1.35
Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood (1998) 1.28
Identification of a consensus mutation in M protein of vesicular stomatitis virus from persistently infected cells that affects inhibition of host-directed gene expression. Virology (1997) 1.17
Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther (2010) 1.14
Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus. J Virol (2008) 1.13
Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology (2012) 1.12
Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. J Virol (2010) 1.07
The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol Ther (2007) 1.07
Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res (2008) 1.06
Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J Virol (2008) 1.05
Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg (2007) 1.05
IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res (2006) 1.01
Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol (2012) 1.01
Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J Virol (2011) 0.95
Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. Mol Ther (2008) 0.94
Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol (2003) 0.92
Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus. Cancer Gene Ther (2010) 0.91
Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death. Int J Cancer (2010) 0.90
Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery (2012) 0.89
Vesicular stomatitis virus as a treatment for colorectal cancer. Cancer Gene Ther (2011) 0.89
The effect of alpha-, beta- and gamma-interferon on the growth of breast cancer cell lines. Anticancer Res (1995) 0.81
Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Res (2003) 0.81
Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells. Arch Dermatol Res (2008) 0.80
Effect of natural interferon-beta on the growth of melanoma cell lines. Melanoma Res (1998) 0.79
Increased caspase-2 activity is associated with induction of apoptosis in IFN-beta sensitive melanoma cell lines. J Interferon Cytokine Res (2010) 0.77
Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors. Surgery (2013) 0.76